PEGylated Proteins Market: By Protein Type (Colony-stimulating Factor, Interferon, Erythropoietin, and Other Protein Types), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic Research Institutes), and Geography

PEGylated Proteins Market size was valued at USD 1.2 billion in 2023 and is poised to grow at 11.9% CAGR over the forecast years to reach USD 2.6 billion by 2030. The PEGylated proteins market refers to the sector involved in the development, production, and distribution of proteins that have been modified through a process called PEGylation. PEGylation involves attaching polyethylene glycol (PEG) chains to proteins. This modification can enhance the therapeutic properties of proteins by increasing their stability, prolonging their half-life in the body, reducing immunogenicity (the likelihood of causing an immune response), and improving their solubility and overall pharmacokinetic profile. These applications span a wide range of medical fields, including oncology, hematology, immunology, and other areas where protein-based therapies are utilized. The growth of the PEGylated proteins market is primarily driven by several key factors. One major factor is the increasing prevalence of chronic diseases such as cancer, kidney diseases, and rheumatoid arthritis.

Moreover, globally, diseases like HIV, tuberculosis, and others contribute to the growing burden of chronic and infectious diseases. This rising disease burden is expected to increase the demand for innovative medicines, thereby boosting research and development efforts focused on proteins, including PEGylated proteins. Furthermore, biotechnology and pharmaceutical companies are increasingly investing in research and development programs. For instance, in March 2022, Flow Eighteen38, a division focused on protein sciences, announced a substantial investment into its protein production and characterization capabilities. Such investments are crucial for advancing protein-based therapies, including PEGylated proteins. Additionally, the adoption of protein-based drugs over non-protein-based drugs is on the rise. PEGylation plays a vital role in this trend by enhancing the circulation and half-life of proteins, thereby improving their efficacy and making them more attractive for therapeutic use. However, key factors hampering the growth of the global PEGylated proteins market include complex and costly development processes, regulatory challenges in proving safety and efficacy, and concerns over immunogenicity and long-term effects, amidst increasing competition from alternative therapies and potential manufacturing scalability issues.

PEGylated Proteins Market Key Developments:

• In July 2022, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of doxorubicin hydrochloride (Celdoxome PEGylated liposomal) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and AIDS-related Kaposi's sarcoma.
• In February 2022, Merck KGaA announced the acquisition of Exelead, a biopharmaceutical CDMO specializing in PEGylated products and complex injectable formulations, including drug delivery technology based on lipid nanoparticles (LNPs).